Eribulin as a Second-line Treatment in Triple-negative Advanced Breast Cancer
Clinical trial NCT05302778 · UNKNOWN
Trial details
- NCT number
- NCT05302778
- Sponsor
- University of Milano Bicocca
- Status
- UNKNOWN
- Study type
- OBSERVATIONAL
- Start date
- 2021-03-22
- Primary completion
- 2023-12-01
- Enrollment
- 200
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.